Meeting
2018 ASCO Annual Meeting
Phase I multicenter trial of CUDC-907 in children and young adults with relapsed/refractory solid tumors, CNS tumors, and lymphomas.
Authors
David Stephen Shulman
Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, MA
David Stephen Shulman , Cecilia Carlowicz , Clay Gustafson , Kieuhoa Tran Vo , Elizabeth Fox , Jodi Ann Muscal , Jeffrey G. Supko , Andrew E. Place , Susan N. Chi , Suzanne Shusterman , Gina Hanna , Jane O'Brien , Suzanne Ezrre , Pei-Chi Kao , Wendy B. London , Steven G. DuBois
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT02909777
Citation
J Clin Oncol 36, 2018 (suppl; abstr 10542)
DOI
10.1200/JCO.2018.36.15_suppl.10542
Abstract #
10542
Poster Bd #
215
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase 1 multicenter trial of CUDC-907 in children and young adults with relapsed or refractory solid tumors, CNS tumors, and lymphoma.
First Author: David Stephen Shulman
Poster
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
First Author: Brian Ko
Poster
2022 ASCO Annual Meeting
A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors.
First Author: Patricia LoRusso
Poster
2018 ASCO Annual Meeting
A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma(WD/DD LPS), solid tumors (ST) and lymphomas (L).
First Author: Todd Michael Bauer